Component
Persistence of HPV positivity
Persistence of HPV positivity. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Among baseline HPV-positive women, 69% on DIM versus 61% on placebo remained positive at six months, RR 1.1 with 95% CI 0.9-1.4.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/dim-research/22075942.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617", "start_char": 0, "end_char": 1631, "text_sha256": "a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617"}
- experimental_model
- Double-blind randomized placebo-controlled trial
- exposure
- Oral DIM 150 mg/day for six months
- limitations
- No demonstrated HPV/cytology benefit; CIN2+ estimates were imprecise. Not evidence that a supplement replaces screening or lesion treatment.
- nutrient_topic
- Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. · 3,3'-Diindolylmethane / DIM
- organism
- 551 women available for analysis
- plain_language
- This trial did not demonstrate improved HPV clearance.
- primary_references
- [dim-p22075942] Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. (2012). https://pubmed.ncbi.nlm.nih.gov/22075942/ DOI: 10.1038/bjc.2011.496
- tissue_or_cell_type
- Low-grade cervical abnormalities and HPV
Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17) · lines 1182–1193
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized placebo-controlled trial · source_derived_draft · unverified_draft
### dim-hpv-null Among baseline HPV-positive women, 69% on DIM versus 61% on placebo remained positive at six months, RR 1.1 with 95% CI 0.9-1.4. Condition category: normal nutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. plain_language: This trial did not demonstrate improved HPV clearance. organism: 551 women available for analysis tissue_or_cell_type: Low-grade cervical abnormalities and HPV experimental_model: Double-blind randomized placebo-controlled trial limitations: No demonstrated HPV/cytology benefit; CIN2+ estimates were imprecise. Not evidence that a supplement replaces screening or lesion treatment. exposure: Oral DIM 150 mg/day for six months evidence_span: {"source_cache": "artifacts/dim-research/22075942.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617", "start_char": 0, "end_char": 1631, "text_sha256": "a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617"} [dim-p22075942] Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. (2012). https://pubmed.ncbi.nlm.nih.gov/22075942/ DOI: 10.1038/bjc.2011.496
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.